Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, VYNE Therapeutics Inc (NASDAQ: VYNE) closed at $1.12 down -7.44% from its previous closing price of $1.21. In other words, the price has decreased by -$7.44 from its previous closing price. On the day, 0.53 million shares were traded. VYNE stock price reached its highest trading level at $1.23 during the session, while it also had its lowest trading level at $1.12.
Ratios:
For a deeper understanding of VYNE Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.47 and its Current Ratio is at 4.47. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on November 18, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 15 ’25 when LEPORE PATRICK G bought 15,000 shares for $2.92 per share. The transaction valued at 43,800 led to the insider holds 51,472 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYNE now has a Market Capitalization of 18664688 and an Enterprise Value of -30044480. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.10 while its Price-to-Book (P/B) ratio in mrq is 0.41. Its current Enterprise Value per Revenue stands at -49.66.
Stock Price History:
The Beta on a monthly basis for VYNE is 1.81, which has changed by -0.44 over the last 52 weeks, in comparison to a change of 0.16260707 over the same period for the S&P500. Over the past 52 weeks, VYNE has reached a high of $4.30, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -3.97%, while the 200-Day Moving Average is calculated to be -45.87%.
Shares Statistics:
For the past three months, VYNE has traded an average of 656.87K shares per day and 552890 over the past ten days. A total of 15.96M shares are outstanding, with a floating share count of 13.63M. Insiders hold about 18.19% of the company’s shares, while institutions hold 36.72% stake in the company. Shares short for VYNE as of 1751241600 were 819146 with a Short Ratio of 1.25, compared to 1748563200 on 334569. Therefore, it implies a Short% of Shares Outstanding of 819146 and a Short% of Float of 4.97.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
A total of 2 analysts believe the company’s revenue will be $150k this quarter.It ranges from a high estimate of $200k to a low estimate of $100k. As of the current estimate, VYNE Therapeutics Inc’s year-ago sales were $198kFor the next quarter, 2 analysts are estimating revenue of $175k. There is a high estimate of $200k for the next quarter, whereas the lowest estimate is $150k.
A total of 2 analysts have provided revenue estimates for VYNE’s current fiscal year. The highest revenue estimate was $800k, while the lowest revenue estimate was $600k, resulting in an average revenue estimate of $700k. In the same quarter a year ago, actual revenue was $501k
